India’s HIV epidemic has changed substantially since the early 2010s, but the size of the country means that even a relatively low national prevalence translates into millions of people living with HIV. The India HIV Estimation 2025 Technical Report estimated that in 2024 about 25.61 lakh people were living with HIV in India and that adult prevalence among people aged 15–49 was approximately 0.20%. The same report estimated about 64,470 new HIV infections and roughly 32,160 AIDS-related deaths during the year.
The direction of travel is encouraging but incomplete. Between 2010 and 2024, annual new HIV infections were estimated to have fallen by about 48.7%, while AIDS-related deaths declined by more than 81%. Those reductions reflect expanded testing, antiretroviral therapy, prevention programs, blood safety, outreach to higher-burden communities, and long-term work under India’s National AIDS Control Programme. The remaining challenge is to accelerate diagnosis and prevention while protecting people living with HIV from stigma and interruptions in treatment so that progress continues toward the 2030 goal of ending AIDS as a public-health threat.
HIV and AIDS Are Different Stages of the Same Infection
HIV is the human immunodeficiency virus, which attacks cells involved in immune defense. AIDS is the most advanced stage of untreated or inadequately controlled HIV infection; it is not a separate virus. Modern antiretroviral therapy can suppress HIV for many years and allow people to live long, healthy lives without progressing to AIDS. The World Health Organization describes HIV as a manageable chronic health condition when effective treatment is available and taken consistently, even though there is not yet a routine cure.
Treatment also has a prevention benefit. When a person living with HIV takes antiretroviral therapy and maintains a sustained undetectable viral load, sexual transmission of HIV does not occur. This principle is commonly summarized as U=U, or Undetectable = Untransmittable, and is explained in CDC’s Undetectable = Untransmittable guidance. Maintaining an undetectable viral load therefore supports both individual health and prevention, which is one reason viral-load monitoring and uninterrupted access to treatment matter so much.
India Has Made Major Progress, but the Epidemic Is Uneven
National averages can hide large differences between states and communities. The 2025 estimation report found that adult prevalence remained above 1% in Mizoram and Nagaland in 2024, with Manipur also substantially above the national average. Other states carry large absolute numbers of people living with HIV because of population size even when prevalence is lower. Prevention and treatment therefore need to be targeted locally rather than based on one nationwide profile.
India’s decline in AIDS-related deaths has been especially strong, reflecting the expansion of treatment and care. New infections have also declined, but more slowly than mortality. That difference matters: when people live longer because treatment works but new infections continue, the total number of people needing lifelong HIV care can remain high or stabilize rather than fall quickly. Progress toward 2030 therefore depends on both maintaining treatment for people already diagnosed and preventing enough new infections to bend the epidemic downward more sharply.
Prevention Requires Multiple Tools, Not One Message
HIV can be transmitted through specific routes, including sexual exposure, sharing contaminated injecting equipment, exposure to infected blood, and transmission from parent to child during pregnancy, birth, or breastfeeding when prevention is not effective. It is not spread by casual contact, hugging, sharing food, ordinary household surfaces, or mosquito bites. Clear communication about those facts remains important because misconceptions create unnecessary fear and stigma while distracting attention from actual prevention.
Prevention includes condoms, regular testing, timely treatment, pre-exposure prophylaxis for people at substantial risk, post-exposure prophylaxis after a potential exposure, sterile injecting equipment, safe blood systems, and prevention of vertical transmission. Programs for people who inject drugs are particularly important in some regions, and treatment for substance dependence can be part of a broader health strategy. Community recovery models such as Alcoholics Anonymous and recovery support are not HIV-prevention programs by themselves, but the broader principle of accessible, nonjudgmental support is relevant whenever substance use, mental health, and infection risk overlap.
Testing and Early Treatment Are Central to the 2030 Goal
People can live with HIV for years without obvious symptoms, so testing is the only reliable way to know status. Earlier diagnosis allows treatment to begin before immune damage becomes advanced and also reduces the period during which a person may unknowingly transmit the virus. India has expanded HIV testing substantially through public programs and targeted interventions, but reaching people who have never tested, people who fear stigma, and communities with limited access remains a major challenge.
The global 95-95-95 framework aims for 95% of people living with HIV to know their status, 95% of those diagnosed to receive antiretroviral treatment, and 95% of those on treatment to achieve viral suppression. The targets are useful because they connect diagnosis, treatment, and effective control rather than measuring only how many medicines were distributed. India’s progress toward 2030 will depend on improving every step of that cascade while preventing treatment interruption when people move, lose income, experience discrimination, or face other social barriers.
Stigma Is Still a Public-Health Problem
HIV stigma can discourage testing, disclosure, treatment adherence, employment participation, relationships, and use of healthcare. People living with HIV should not be treated as dangerous in ordinary social settings, and healthcare workers should use evidence-based infection-control procedures rather than fear-driven exclusion. The issue is both practical and ethical: moral principles in healthcare such as respect, confidentiality, fairness, and nonmaleficence directly affect whether people feel safe seeking diagnosis and treatment.
Stigma can be especially harmful when it intersects with gender, sexuality, drug use, migration, or poverty. Prevention programs work better when communities can access condoms, testing, PrEP, sterile equipment, treatment, and counseling without expecting humiliation or punishment. Public-health progress therefore depends not only on clinics and medicines but also on trust. When people believe that a positive diagnosis will destroy their social or economic life, they have a stronger incentive to avoid the very services that could protect them and others.
Conclusion
India has made substantial progress against HIV: adult prevalence remained low nationally in 2024, new infections were roughly half their 2010 level, and AIDS-related deaths had fallen by more than four-fifths. Yet approximately 25.61 lakh people were still living with HIV, and the epidemic remains more intense in certain states and populations. The path toward 2030 requires faster prevention of new infections, wider and earlier testing, uninterrupted antiretroviral treatment, reliable viral-load monitoring, strong programs for higher-burden communities, and continued work against stigma. HIV is now manageable for many people, but maintaining that progress depends on treating prevention, treatment, and human dignity as parts of the same public-health strategy.